Your browser is no longer supported. Please, upgrade your browser.
Settings
ANIX Anixa Biosciences, Inc. daily Stock Chart
ANIX [NASD]
Anixa Biosciences, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own5.40% Shs Outstand20.63M Perf Week21.25%
Market Cap71.79M Forward P/E- EPS next Y-0.57 Insider Trans3.00% Shs Float18.45M Perf Month6.75%
Income-14.90M PEG- EPS next Q-0.22 Inst Own6.60% Short Float5.70% Perf Quarter-5.18%
Sales0.30M P/S239.31 EPS this Y25.90% Inst Trans- Short Ratio15.20 Perf Half Y-20.00%
Book/sh0.26 P/B13.38 EPS next Y17.40% ROA-170.20% Target Price8.00 Perf Year-19.07%
Cash/sh0.29 P/C12.17 EPS next 5Y- ROE-202.10% 52W Range2.74 - 5.70 Perf YTD6.10%
Dividend- P/FCF- EPS past 5Y11.80% ROI-228.70% 52W High-38.95% Beta0.67
Dividend %- Quick Ratio4.10 Sales past 5Y-41.60% Gross Margin- 52W Low27.01% ATR0.26
Employees7 Current Ratio4.10 Sales Q/Q- Oper. Margin- RSI (14)57.22 Volatility11.94% 8.19%
OptionableNo Debt/Eq0.00 EPS Q/Q63.60% Profit Margin- Rel Volume1.36 Prev Close3.55
ShortableYes LT Debt/Eq0.00 EarningsOct 25 Payout- Avg Volume69.19K Price3.48
Recom- SMA2014.59% SMA500.61% SMA200-12.30% Volume93,757 Change-1.97%
Jan-06-20 07:00AM  Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference PR Newswire
Jan-02-20 05:25AM  Investors Who Bought Anixa Biosciences (NASDAQ:ANIX) Shares Three Years Ago Are Now Down 38% Simply Wall St. -8.54%
Dec-23-19 07:00AM  Anixa Biosciences to Present at Biotech Showcase 2020 PR Newswire
Dec-16-19 06:45AM  Anixa Biosciences Announces Commercial Launch of Cchek Prostate Cancer Confirmatory Test PR Newswire
Dec-13-19 05:45PM  Anixa Biosciences to Host Conference Call to Discuss Plans for 2020 PR Newswire -15.10%
06:45AM  Anixa Biosciences Provides Update on CAR-T Program PR Newswire
Dec-02-19 07:00AM  Anixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium PR Newswire
Nov-26-19 07:00AM  Anixa Biosciences Announces Genesis Research to Join Cchek Prostate Cancer Study PR Newswire +7.29%
Nov-22-19 07:00AM  Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek Prostate Cancer Study PR Newswire
Nov-20-19 07:00AM  Anixa Biosciences Announces Collaboration with Idaho Urologic Institute on Cchek Prostate Cancer Study PR Newswire
Nov-07-19 07:00AM  Anixa Biosciences Announces Presentation at Cell Symposia: Hallmarks of Cancer PR Newswire
Nov-05-19 07:00AM  Anixa Biosciences Announces Patent Issued for its Breast Cancer Vaccine PR Newswire
Nov-03-19 07:38AM  What Kind Of Shareholders Own Anixa Biosciences, Inc. (NASDAQ:ANIX)? Simply Wall St.
Oct-28-19 07:00AM  Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board PR Newswire
Oct-25-19 07:00AM  Anixa Biosciences Announces Collaboration with Urology San Antonio on Cchek Prostate Cancer Study PR Newswire
Oct-22-19 07:00AM  Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) PR Newswire
Oct-15-19 07:00AM  Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts PR Newswire +5.11%
Oct-10-19 07:00AM  Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board PR Newswire
Sep-23-19 07:00AM  Anixa Biosciences Announces University of Maryland School of Medicine to Join Cchek Prostate Cancer Study PR Newswire
Sep-19-19 07:53AM  Should You Worry About Anixa Biosciences, Inc.'s (NASDAQ:ANIX) Cash Runway? Simply Wall St.
07:00AM  Anixa Biosciences Commences Collaboration with Potomac Urology Center on Cchek Prostate Cancer Study PR Newswire
Sep-16-19 07:00AM  Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree PR Newswire
Aug-26-19 07:00AM  Anixa Biosciences to Present at Two Upcoming Investor Conferences PR Newswire
Jul-29-19 07:00AM  Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek Prostate Cancer Study PR Newswire
Jul-24-19 07:00AM  Anixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology PR Newswire +5.25%
Jul-23-19 01:22PM  Have Insiders Been Buying Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares? Simply Wall St.
Jul-22-19 07:00AM  Anixa Biosciences Announces U.S. Department of Veterans Affairs VA Maryland Health Care System Joins Cchek Prostate Cancer Study PR Newswire
Jul-17-19 12:25PM  Anixa Bioscience's Deal With Cleveland Clinic Sends Shares Higher Benzinga +13.08%
07:00AM  Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology PR Newswire
Jul-16-19 07:00AM  Anixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived Suppressor Cells PR Newswire
May-29-19 07:00AM  Anixa Biosciences to Present at the CYTO 2019 - 34th Congress of the International Society for Advancement of Cytometry PR Newswire
May-24-19 02:56PM  What Type Of Shareholder Owns Anixa Biosciences, Inc.'s (NASDAQ:ANIX)? Simply Wall St.
May-21-19 07:00AM  Anixa Biosciences to Present at the Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum PR Newswire
May-13-19 07:00AM  Anixa Biosciences Announces Completion of Cchek Analytical Verification at CLIA Laboratory PR Newswire
May-02-19 07:00AM  Anixa Biosciences to Present at B. Riley FBR Institutional Investor Conference PR Newswire
Apr-17-19 07:00AM  US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology PR Newswire
Apr-11-19 07:00AM  Anixa Biosciences Extends and Expands its Collaboration with New Jersey Urology PR Newswire
Apr-03-19 02:00PM  Anixa Biosciences Presents Cchek Prostate Cancer Detection Data at AACR Annual Meeting PR Newswire
Mar-27-19 07:00AM  Anixa Biosciences CEO to Present at the New York Academy of Sciences Symposium on Cancer Immunotherapy PR Newswire
Mar-25-19 07:00AM  U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek Prostate Cancer Study PR Newswire
Mar-14-19 07:00AM  Anixa Biosciences Announces Notice of Allowance for Additional Cancer Detection Technology Patent PR Newswire
Mar-13-19 12:48PM  Does Anixa Biosciences, Inc. (NASDAQ:ANIX) Have A Volatile Share Price? Simply Wall St.
Mar-04-19 07:00AM  Anixa Biosciences to Present Cchek Technology and Data at the Molecular Medicine Tri-Conference PR Newswire
Feb-28-19 07:00AM  Anixa Biosciences to Present Latest Prostate Cancer Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting PR Newswire
Feb-25-19 07:00AM  Anixa Biosciences Announces Partnership with ResearchDx for Launch of Cchek Prostate Cancer Confirmation Test PR Newswire
Feb-21-19 07:00AM  Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D. PR Newswire
Feb-13-19 07:00AM  Anixa Biosciences to Present at Moffitt Cancer Center's Business of Biotech Conference PR Newswire
Feb-05-19 11:17AM  What Are Analysts Saying About Anixa Biosciences, Inc.s (NASDAQ:ANIX) Earnings Trajectory? Simply Wall St.
Jan-25-19 07:00AM  Anixa Biosciences Conference Call Recording Available on Company Website PR Newswire -9.92%
Jan-24-19 07:00AM  Anixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance PR Newswire +9.29%
Jan-16-19 07:30AM  Anixa Biosciences to Hold Conference Call to Discuss Outlook for 2019 PR Newswire +8.31%
Dec-26-18 11:05AM  Should You Take Comfort From Insider Transactions At Anixa Biosciences, Inc. (NASDAQ:ANIX)? Simply Wall St. +5.25%
Dec-19-18 07:00AM  Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek Cancer Diagnostic Test PR Newswire
Dec-03-18 07:00AM  Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference PR Newswire
Nov-15-18 07:00AM  Anixa Biosciences To Present Cchek Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy PR Newswire +5.83%
Nov-12-18 07:00AM  Anixa Biosciences Presents Positive Data from its Artificial Intelligence Powered Liquid Biopsy for Prostate Cancer at SITC Conference PR Newswire
Oct-29-18 07:00AM  Anixa Biosciences to Present at SITC Annual Meeting PR Newswire
Oct-24-18 07:00AM  Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek Cancer Diagnostic Test PR Newswire
Oct-22-18 07:00AM  Moffitt Cancer Center and Anixa Biosciences Announce Completion of Pre-IND Meeting with FDA for CAR-T Therapy PR Newswire -28.24%
Oct-17-18 07:00AM  Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference PR Newswire
Oct-16-18 10:59AM  Are Anixa Biosciences Incs (NASDAQ:ANIX) Interest Costs Too High? Simply Wall St.
Oct-15-18 07:00AM  Anixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek Artificial Intelligence based Cancer Detection Technology PR Newswire +14.26%
Oct-11-18 07:00AM  Anixa Biosciences Appoints Leading Researchers in Immuno-Oncology to its Scientific Advisory Board PR Newswire -7.11%
Oct-05-18 07:00AM  Anixa Biosciences to Present at Artificial Intelligence Conference PR Newswire
Anixa Biosciences, Inc., a cancer-focused biotechnology company, develops both diagnostics and therapeutics to detect cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs, which genetically engineer a patient's own immune cells to fight cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Titterton Lewis H jrDirectorJan 15Buy3.325,00016,600918,944Jan 16 11:22 AM
Titterton Lewis H jrDirectorJan 14Buy3.227,40023,828913,944Jan 15 10:57 AM
KUMAR AMITChief Executive OfficerJan 14Buy2.9920,00059,800194,000Jan 14 10:47 AM